Evidence map›Paper›PMID 37901716›Full record

ArticleJournal of hepatocellular carcinoma2023

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.

Hsiao-Mei Hsu, Hsin-I Tsai, Wei-Chen Lee, Chih-Chi Wang, Ming-Chin Yu, Shi-Ming Lin, Chun-Yen Lin, Chi-Huan Wu, Chao-Wei Lee

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hsiao-Mei HsuDepartment of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Hsin-I TsaiDepartment of Anesthesiology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Wei-Chen LeeCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0002-8627-1324
Chih-Chi WangDivision of General Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Ming-Chin YuGraduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0002-6980-7123
Shi-Ming LinCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chun-Yen LinCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0003-3007-3190
Chi-Huan WuCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chao-Wei LeeGraduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0002-6853-4557

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection remains one of the most effective curative therapies for HCC. However, the majority of patients have advanced unresectable diseases upon presentation. It is of paramount importance to raise the resectability of patients with HCC. The remarkable objective response rate reported by Phase III IMbrave150 trial has led to the concept of "Atezo/Bev followed by curative conversion (ABC conversion)" for initially unresectable HCC. With this revolutionary treatment strategy, the concept of surgical resection for HCC should be amended. The current opinion illustrated three extended surgical concepts, which could be integrated into clinical practice in the era of immune checkpoint inhibitors (ICI).

Indexed as

hepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyliver resectionsurgery

Identifiers

PMID37901716
PMCPMC10612521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.